The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
Site Search
With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.
As a volunteer, you’ll join thousands of people across the country who are helping add tomorrows to the lives of people with cystic fibrosis.
Recipients include eight innovative programs from around the country that serve the CF community.
Watch the entire leadership conference, including all of the break-out sessions and Medical Hot Topics, from start to finish.